Peder Holk Nielsen to become president and CEO of Novozymes

With effect from 1 April

Danish enzymes manufacturer Novozymes has appointed Peder Holk Nielsen as president and chief executive officer. He takes up the role on 1 April, succeeding Steen Riisgaard, who steps down after 12 years in the role.

Holk Nielsen is currently Novozymes’ executive vice president and head of the Enzyme Business, a position he has held since 2007. Prior to this, his career spans management positions in Novozymes and Novo Industri/Novo Nordisk across business development, R&D, quality management and sales and marketing.

Steen Riisgaard steps down after 12 years at the company’s top post and 33 years at Novozymes and Novo Industri/Novo Nordisk.

Since 2000, Novozymes has delivered average annual growth rates of 7–8% and increased returns of invested capital from 10–20%. The company now holds 47% of the global market for industrial enzymes and spearheads the increasing use of micro-organisms and industrial biotechnology products across a range of industries.

The new executive leadership team at 1 April, will comprise:

  • President and CEO: Peder Holk Nielsen
  • Business Development: EVP Thomas Videbæk
  • Business Operations: EVP Andrew Fordyce
  • Supply Operations: EVP Thomas Nagy
  • Research & Development: EVP and CSO Per Falholt
  • Corporate Functions: EVP and CFO Benny Loft

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Let enzymes do the work

The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.
Subscribe now